ICH Reflection Paper

Further Opportunities for Harmonization of Standards for Generic Drugs

ICH Reflection Paper

Executive Summary

This reflection paper outlines a strategic approach for developing and enhancing ICH guidelines to support the harmonization of scientific and technical standards for generic drugs. As part of this approach, this paper outlines recommendations to develop a series of ICH guidelines on standards for demonstrating equivalence (e.g., bioequivalence) for (1) non-complex dosage forms and (2) more complex dosage forms and products. To accomplish this work, it is proposed to establish a generic drug discussion group to assist in assessing the feasibility of harmonization of standards for generic drugs and to prioritize work areas.

ICH is uniquely positioned to develop and implement these recommendations given its reforms in 2015 establishing it as the global venue for harmonization of standards for pharmaceutical products, including both new drugs and generic drugs. Although many ICH guidelines are applicable to generic drugs (e.g., ICH Quality Guidelines), historically ICH has focused on standards for new drugs. As a result, there are areas of great interest to generic drug regulators and developers where internationally harmonized guidance is lacking or where international harmonization could potentially lead to improved access to lower cost generic medicines. Generic drugs supply a significant portion (>50%) of the pharmaceutical market of the ICH Member and Observer regions and harmonization in this area presents opportunities for market competition, cost savings, and greater supply, thereby increasing patient access to pharmaceutical products globally. There would be a significant public health benefit in utilizing ICH’s highly efficient and successful process to harmonize standards for generic drugs.

Below, we discuss the benefits of harmonization of standards for generic drugs and elaborate on our recommendations for proceeding with harmonization for generic drugs under ICH.

I. Proposed harmonization work should be targeted at scientific and technical standards for generic drugs

The mission of ICH is to achieve greater harmonization in the interpretation and application of technical guidelines for pharmaceuticals, and the harmonization of standards for generic drugs falls squarely within

1 A generic drug product generally contains a small molecule active ingredient and an applicant obtains market access in different regions by demonstrating sameness or equivalence to an already marketed reference product, thus leveraging safety and efficacy data versus needing to provide independent data to demonstrate clinical safety and efficacy. Individual drug regulatory authorities may differ in the scope of this type of approval and may have different regulatory definitions of a generic drug.
this mission. However, it is acknowledged that legal and regulatory requirements for generic drugs are not aligned across jurisdictions. For example:

- In the U.S., the Food and Drug Administration (FDA) does not allow a generic drug and its reference product to be different oral dosage forms (e.g., tablets and capsules). In contrast, in the European Union, the competent drug regulatory authorities allow a generic drug and its reference product to be different oral dosage forms if the product meets bioequivalence criteria. Both regions may request a bioequivalence study as the scientific evidence needed to support marketing approval of different oral dosage forms but evaluate that study through different regulatory pathways.

- The U.S. FDA currently requires that the reference product used in testing to support approval (i.e., the “reference standard” for generic drug comparison as referred to in U.S. statutory text, not to be confused with a compendial reference standard) be registered in the United States. Not all ICH Members require that the reference product be marketed or registered in their country or region, as some permit the use of foreign sourced reference products.² For example, Health Canada outlines the criteria for the use of a foreign sourced reference product when demonstrating equivalence of the generic drug to the Canadian Reference Product (e.g., proof of similarity between domestic and foreign sourced reference products).³

- In Japan’s Pharmaceuticals and Medical Devices Agency, the granting of biowaivers for specific classes of drugs and additional strengths may be limited due to the regulatory framework and scientific issues. Additionally, in Japan, biowaivers for additional strengths may be an issue related to Pharmacopeia standards.

Instead of harmonizing regional legal and regulatory requirements, it is proposed to develop and enhance ICH guidelines in scientific and technical areas that would be valuable and achievable across multiple regulatory pathways and where there is common interest in harmonization.

II. Harmonization of scientific and technical standards for generic drugs could improve public health and health systems domestically and internationally

Generic drugs are often the product of a global supply chain and produced with the intent to market in multiple jurisdictions. They comprise a significant portion of the pharmaceutical market in developed countries, including 89 percent of dispensed medicines in the United States,④ 56 percent of prescribed


medicines in Europe, and 60 percent of the market share in Japan, and as such, constitute a critical part of the healthcare system in these and other regions globally. Generic drugs’ portion of the pharmaceutical market in developing countries is even higher.

At present, a lack of harmonized standards reduces the number of potential markets in which data and information submitted in support of a generic drug marketing application can be used by a developer to support marketing authorization in another jurisdiction. This can lead to monopolies or limited sources of drugs in those markets in which approval is not sought due to the additional development burdens. By contrast, harmonization may allow developers to use the data submitted in support of a generic drug marketing application to meet multiple jurisdictions’ regulatory requirements for marketing authorization. In addition, harmonization may increase the size of generic drug markets and thereby attract more competition from developers, lower costs by increasing the number of market entrants, and expand patient access in jurisdictions in which developers otherwise may have decided not to pursue marketing authorization due to differences in scientific and technical standards that require additional expensive studies in each jurisdiction.

In addition, harmonization may streamline generic drug development and make it more cost effective, including by potentially reducing the number of duplicative studies (e.g., bioequivalence studies) that are required to meet the standards for more than one jurisdiction. This also may lead to a reduced number of human subjects that are required for these studies. Duplicative bioequivalence studies may place participants at additional risk and delay patient access to more affordable medicines. For some studies requiring patients with certain specific diagnoses, duplicative studies can exhaust the available human subjects or may require extended recruitment periods which leads to delays in completion of studies. These challenges may also limit the number of manufacturers that enter the market thereby delaying patient access to more affordable medicines. This is already the case for generic versions of certain oncology drugs targeting relatively rare types of cancer.

Finally, harmonization may increase the quality of generic medicines by establishing a globally consistent culture of quality and moving compliance with quality standards in a common direction. For example, a pharmaceutical company may have two or more manufacturing lines – one that is subject to domestic regulatory standards and others that are subject to different foreign regulatory standards. This potentially results in greater cost, an increase in the likelihood of error in applying the correct regulatory and scientific standards, and in the complexity of recordkeeping.


III. Recommendations

The development of the ICH M9 and M10 Guidelines on *Biopharmaceutics Classification System-based Biowaivers* and *Bioanalytical Method Validation* represent the first step towards harmonization of standards for generic drugs. Subsequent work can build on these guidelines and further expand to additional topic areas including standards for demonstrating equivalence.

a. Develop a series of ICH guidelines on standards for demonstrating equivalence (e.g., bioequivalence) for non-complex dosage forms

It is proposed to begin with development of guideline(s) on bioequivalence studies for immediate-release oral dosage forms, as these products constitute a significant portion of submissions to regulatory authorities. This work would include development of guidance on bioequivalence study design (e.g., crossover vs. parallel, subject, sample size, fasting vs. fed, replicate design) and data analysis (e.g., statistical methods for BE assessment, handling outlier data, average bioequivalence vs. scaled bioequivalence, parent vs. metabolite). As part of this work, a working group could consider the feasibility of harmonizing bioequivalence standards and work to align them to the extent possible. Special considerations for narrow therapeutic index drugs and highly variable drugs including drugs with non-linear kinetics might also be included.

It is noted that such a harmonized bioequivalence study design could be expanded to include additional study arms to accommodate more than one reference product for bridging purposes. For example, a three-way crossover study may allow generic drug manufacturers to submit data from the same study using one test product in support of marketing approval in more than one region.

It is also acknowledged that the requirements to support waivers of bioequivalence studies for non-biostudy strengths are not harmonized. The work under this series of guidelines could include developing harmonized requirements for biowaivers for additional strengths within a product line.

Another work stream under this topic may also include harmonization of biowaivers for solutions such as oral and injectable solutions.

b. Develop a series of ICH guidelines on standards for demonstrating equivalence (e.g., bioequivalence) for more complex dosage forms or products

Following the development of ICH guideline(s) on non-complex dosage forms, it is proposed to develop guidelines on more complex dosage forms or products. One such guideline may address bioequivalence studies for modified-release oral dosage forms, which could address scientific considerations such as “waivers” for additional strengths for modified-release products and when partial Area Under the Curve (pAUC) measurements may be important. In addition, other guidelines could address pharmaceutical equivalence and bioequivalence standards for products with complex active pharmaceutical ingredients.
IV. Establish a generic drug discussion group and linkages with other international initiatives on generics

As a near-term next step, it is proposed that ICH establish a discussion group to further consider the specific areas and opportunities for harmonized guidelines as outlined in the recommendations under section III. Additionally, the discussion group could conduct a review of existing ICH Guidelines to assess whether there are any gaps in existing guidance for generic drugs and make proposals for revision of ICH Guidelines as necessary (see Annex I). Given that the harmonization process is resource intensive and time consuming, the discussion group could serve to prioritize work areas and ensure that priorities are set carefully.

The discussion group could primarily interact through email correspondences and teleconferences, or via face-to-face meetings, as appropriate. The discussion group’s responsibilities would include:

- Revising this reflection paper based on regional input
- Establishing an overarching vision for the harmonization of generic drug standards under ICH
- Identifying new topics for harmonization of generic drug standards (considering the areas identified in sections III.a and III.b of this paper)
- Surveying existing ICH guidelines as well as relevant WHO guidelines related to generic drug standards to identify any gaps in guidance for generic drugs
- Working with the ICH implementation subcommittee to assess consistency in the regional implementation of ICH guidelines for generic drugs
- Prioritizing areas for harmonization and making recommendations to the ICH Management Committee

Additionally, it is acknowledged that international collaborative initiatives are ongoing on issues relating to generic medicines. For example, the International Generic Drug Regulators Programme (IGDRP), now within the International Pharmaceutical Regulators Programme (IPRP), has published or provided input into several informative papers on international guidelines and expectations for generic products, including:

---

7 It is noted that a quality discussion group will be stood up under ICH to assess the need for modernization or revision of any existing ICH Quality Guidelines. This discussion group could also assess whether there is a need to make any revisions for quality aspects for generic drugs that may be unique from new drugs (e.g., sameness of active substance).
• IGDRP Generic Drug Product Regulatory Gap Analysis[^8];
• International Guidelines for Bioequivalence of Systemically Available Orally Administered Generic Drug Products: A Survey of Similarities and Differences[^9];
• A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme[^10].

Additionally, WHO’s Prequalification of Medicines Programme helps ensure that medicines purchased by or through international procurement agencies for resource-limited countries meet acceptable standards of quality, safety, and efficacy. Through this program, several guidelines have been developed and should be considered by the ICH discussion group to avoid any inconsistencies, as appropriate.

This discussion group should leverage prior work that has been done to date and take measures to avoid duplication of work that continues in other international fora.

Establishment of this discussion group will allow for the necessary scientific and technical engagement and communication between experts to advance harmonization of guidance for generic drugs.

V. Conclusion

Harmonization of technical and scientific standards for generic drugs presents an opportunity for significant public health benefits by streamlining drug development across regulatory jurisdictions and increasing patient access globally to high quality affordable pharmaceuticals. It is recommended that ICH initiate topics where a need for harmonization seems most feasible and where agreement exists among ICH parties. As experience is gained, ICH may refocus its harmonization efforts to more complex topic areas where harmonization may not seem feasible at present. To assist in this effort, it is recommended that as a next step, ICH establish a discussion group to assess the feasibility of harmonization of various topic areas specific to standards for generic drugs and to assist in prioritizing work areas to ensure appropriate use of resources.

[^9]: AAPS Journal, Vol. 15, No. 4, October 2013
[^10]: J Pharm Pharm Sci, 21, 27 - 37, 2018
Annex 1

Table 1 below identifies existing ICH Guidelines that might be revised to include recommendations for generic drugs (left column) as well as guidelines that likely would not have to be revised (right column) because they are not relevant to generic drugs. For example, the following Efficacy guidelines might be revised to include recommendations on:

- The conduct of comparative clinical endpoint bioequivalence studies: E3, E6, E8, E9, E10, E17
- Pharmacovigilance for generic drugs: E2
- Identification of products with a narrow therapeutic index: E4
- Statistical considerations for bioequivalence: E9

However, as indicated in Table 1, guidelines related to the generation of new safety or efficacy data (E2A, E14, and E19) would generally not be applicable to the generic drug development process.

**Table 1: Efficacy Guidelines**

<table>
<thead>
<tr>
<th>Efficacy guidelines that have an impact on the generic drug industry and may potentially need to be revised</th>
<th>Efficacy guidelines that do not have an impact on the generic drug industry and likely do not need to be revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>- E2C(R2) Periodic Benefit-Risk Evaluation Report</td>
<td>- E1 Clinical Safety for Drugs used in Long-Term Treatment</td>
</tr>
<tr>
<td>- E2C(R2) Q&amp;As Questions &amp; Answers: Periodic Benefit-Risk Evaluation Report</td>
<td>- E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting</td>
</tr>
<tr>
<td>- E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting</td>
<td>- E2B(R3) Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports</td>
</tr>
<tr>
<td>- E2E Pharmacovigilance Planning</td>
<td>- E2B(R3) IWG Implementation: Electronic Transmission of Individual Case Safety Reports</td>
</tr>
<tr>
<td>- E2F Development Safety Update Report</td>
<td>- E5 Ethnic Factors</td>
</tr>
<tr>
<td>- E3 Clinical Study Reports</td>
<td>- E7 Clinical Trials in Geriatric Population</td>
</tr>
<tr>
<td>- E4 Dose-Response Studies</td>
<td>- E11 - E11A Clinical Trials in Pediatric Population</td>
</tr>
<tr>
<td>- E6 Good Clinical Practice</td>
<td>- E12 Clinical Evaluation by Therapeutic Category</td>
</tr>
<tr>
<td>- E8 General Considerations for Clinical Trials</td>
<td>- E14 Clinical Evaluation of QT</td>
</tr>
<tr>
<td>- E9 Statistical Principles for Clinical Trials</td>
<td>- E15 Definitions in Pharmacogenetics/Pharmacogenomics</td>
</tr>
<tr>
<td>- E10 Choice of Control Group in Clinical Trials</td>
<td>- E16 Qualification of Genomic Biomarkers</td>
</tr>
<tr>
<td>- E17 Multi-Regional Clinical Trials</td>
<td>- E18 Genomic Sampling</td>
</tr>
<tr>
<td></td>
<td>- E19 Safety Data Collection</td>
</tr>
</tbody>
</table>
Annex II

Remit of the Informal Generic Drug Discussion Group

_Endorsed by the ICH Management Committee on 30 January 2019_

**General Description**

The Informal Generic Drug Discussion Group (IGDG) will serve as a technical discussion group for issues relevant to harmonisation of scientific and technical standards for generic drugs. The IGDG will recommend areas for harmonisation under ICH and assess feasibility of harmonisation of various topic areas within existing regional regulatory frameworks.

The IGDG will operate in line with the applicable ICH procedures, similar to other ICH Technical/Discussion Groups, under the oversight of the ICH Management Committee (MC), with reporting to the ICH Assembly. As the remit of ICH is to harmonise technical standards, the IGDG should in its work remain focused on technical and scientific issues. Matters related to statutory and regulatory parameters are strictly beyond the scope of the remit of this IGDG; these matters fall under the remit of the regulatory authorities in different jurisdictions.

**Duration of Tenure**

The discussion group (DG) will serve for a period of one-year. Thereafter, the MC will consider whether this DG should sunset or whether additional work merits its continuation for another specified term.

**Scope of Activities**

- Identification of specifically recommended new topics for harmonisation under ICH that are deemed highest priority in the near term
- Review any ICH topic proposals related to standards for generic drugs and make recommendations for any revisions or resequencing of work, as needed and requested by the ICH MC
- Survey of existing ICH Efficacy and Multidisciplinary guidelines as well as relevant WHO guidelines related to generic drug standards to assess for any gaps in guidance for generic drugs
- Recommended prioritization of other topic areas for future generic drug-related harmonisation work under ICH

_The Informal Generic Drug Discussion Group should endeavour to complete the following activities within the initial one-year term:_

- Review any ICH topic proposals related to standards for generic drugs and make recommendations for any revisions or resequencing of work, as needed and requested by the ICH Management Committee
- Identify priority topic areas for harmonisation under ICH that would present public health benefit and would be feasible for harmonisation given existing regional regulatory frameworks.
The DG will serve to identify converging views around areas that would be viewed as valuable harmonisation projects for generic drug standards that could be undertaken in the near term.

A single party would volunteer to submit the topic proposal(s) through the annual topics process for the Assembly’s consideration.

- Conduct a survey of existing ICH Efficacy and Multidisciplinary Guidelines to assess any gaps in guidance for generic drugs and make recommendations for revisions to existing ICH guidelines. Additionally, relevant WHO guidelines related to generic drug standards should be reviewed to align guidance and avoid duplication of effort where appropriate.
  - The DG should collaborate with the Informal Quality Discussion Group, as appropriate, in assessment of existing Quality guidelines.

- Recommend a prioritization for harmonisation work for standards for generic drugs including any sequencing of new topics and revision of existing guidelines.

Type of Expertise Needed and Resources

The IGDG should be comprised of a diverse group of strategically-oriented experts that collectively have extensive knowledge of the scientific and regulatory aspects related to bioequivalence, pharmacokinetics (PK), PK study design, biostatistical methods for bioequivalence evaluation, biopharmaceutics, and in vitro dissolution.

It is envisioned that the IGDG should be comprised of experts from Members and Observers of the ICH Assembly, in accordance with the applicable Articles of Association, Rules of Procedure, and Standard Operating Procedures. ICH Members and Observers participating in the IGDG should be allowed to nominate standing experts and alternate experts to enable an appropriate balance of expertise while keeping the size of the IGDG manageable, in accordance with the applicable Standard Operating Procedures.

Operating Model and Term

The IGDG should complete its activities in a virtual setting via email and teleconference. In exceptional cases, the ICH Management Committee (MC) may consider granting a face-to-face meeting of the IGDG during a biannual ICH Meeting upon approval of a specific work plan in line with current practice for other ICH Working Groups.

The leadership of the IGDG should be comprised of a Rapporteur and a Regulatory Chair, in accordance with the applicable Standard Operating Procedures.

The IGDG will operate for a 1-year term beginning on the date following the approval of the IGDG remit by the ICH MC when the membership of the IGDG is confirmed. The IGDG should provide an update of its activities and progress to the ICH MC within 3 months after its initiation and then update at least biannually (or more frequently upon request) to the ICH MC and the ICH Assembly, in line with current practice for other ICH Working Groups. At the end of the initial 1-year term, the ICH MC will consider whether to grant an extended term to the IGDG.
### Potential Timeline for Specific Tasks*

<table>
<thead>
<tr>
<th>Expected future completion date</th>
<th>Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Month 1</strong></td>
<td>Initial call to discuss the DG work plan</td>
</tr>
<tr>
<td><strong>Month 2 – 3</strong></td>
<td>Discuss and review any ICH topic proposal(s) related to standards for generic drugs, if needed and requested by the ICH MC</td>
</tr>
<tr>
<td><strong>Month 4</strong></td>
<td>Review existing WHO guidelines</td>
</tr>
<tr>
<td><strong>Month 4 or 5</strong></td>
<td>T-con with the ICH Informal Quality Discussion Group (IQDG)</td>
</tr>
<tr>
<td><strong>Month 5 – 7</strong></td>
<td>Identify priority guidelines or guideline series on recommended areas for harmonisation on standards for demonstrating BE</td>
</tr>
<tr>
<td><strong>Month 8 – 9</strong></td>
<td>Review existing ICH Efficacy and Multidisciplinary Guidelines to assess a need for revision to add additional guidance for considerations for generic drug standards</td>
</tr>
<tr>
<td><strong>Month 10</strong></td>
<td>Finalize DG recommendation on any proposed revisions to ICH Guidelines</td>
</tr>
<tr>
<td><strong>Month 11 – 12</strong></td>
<td>DG finalizes overall recommendations and prioritizes work areas</td>
</tr>
</tbody>
</table>

*Note: The IGDG will review this timeline once established and consider whether any modification is necessary to optimize the timing and sequencing of events e.g. teleconference with the IQDG.*